ライフサイエンスコーパス: non-Hodgkin's lymphoma

1 t context, and disease type (except possibly non-Hodgkin's lymphoma).

2 ity in the treatment of multiple myeloma and non-Hodgkin's lymphoma.

3 s for improving the outcome in patients with non-Hodgkin's lymphoma.

4 b has improved the outcome for patients with non-Hodgkin's lymphoma.

5 ntibodies is an effective therapy for B-cell non-Hodgkin's lymphoma.

6 ing of Jordan, died after a long battle with non-Hodgkin's lymphoma.

7 results in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

8 arker of poor prognosis in aggressive B cell non-Hodgkin's lymphoma.

9 esently being defined for both Hodgkin's and non-Hodgkin's lymphoma.

10 lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma.

11 advanced solid tumors or relapsed/refractory non-Hodgkin's lymphoma.

12 with proven efficacy in multiple myeloma and non-Hodgkin's lymphoma.

13 e has been suggested to increase the risk of non-Hodgkin's lymphoma.

14 cluding multicentric Castleman's disease and non-Hodgkin's lymphoma.

15 et for the treatment of multiple myeloma and non-Hodgkin's lymphoma.

16 myeloma and is being studied for therapy of non-Hodgkin's lymphoma.

17 btained in a heavily pretreated patient with non-Hodgkin's lymphoma.

18 1.03, 1.38) were associated moderately with non-Hodgkin's lymphoma.

19 high-dose HCT, particularly in patients with non-Hodgkin's lymphoma.

20 lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma.

21 nding the role of familial susceptibility in non-Hodgkin's lymphoma.

22 ell lymphoma (DLCL), the most common form of non-Hodgkin's lymphoma.

23 distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma.

24 atment of other B-cell neoplasias, including non-Hodgkin's lymphoma.

25 gnancies including HD and select subtypes of non-Hodgkin's lymphoma.

26 neic blood transfusion increases the risk of non-Hodgkin's lymphoma.

27 as originally developed for the treatment of non-Hodgkin's lymphoma.

28 rual and reproductive factors in the risk of non-Hodgkin's lymphoma.

29 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

30 othelioma, and 0.97 (95% CI: 0.65, 1.44) for non-Hodgkin's lymphoma.

31 survival in patients with aggressive B-cell non-Hodgkin's lymphoma.

32 tastatic melanoma, renal cell carcinoma, and non-Hodgkin's lymphoma.

33 ma (FL) is the most common form of low-grade non-Hodgkin's lymphoma.

34 herapy agent for further development against non-Hodgkin's lymphoma.

35 common malignancies are Kaposi's sarcoma and non-Hodgkin's lymphoma.

36 verexpressed in B-cell malignancies, such as non-Hodgkin's lymphoma.

37 equired for GC formation and associated with non-Hodgkin's lymphoma.

38 ic cancer, and 2.31 (95% CI: 1.48, 3.61) for non-Hodgkin's lymphoma.

39 ive therapeutic target for high-grade B cell non-Hodgkin's lymphoma.

40 still eludes most patients with leukemia and non-Hodgkin's lymphoma.

41 eatment for first-line therapy of follicular non-Hodgkin's lymphoma.

42 re lymphomas and included both Hodgkin's and non-Hodgkin's lymphoma.

43 provide an optimal ADC for the treatment for non-Hodgkin's lymphoma.

44 ated cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.

45 valuated for all malignant lymphomas and for non-Hodgkin's lymphoma.

46 in circulating tumor cells in a patient with non-Hodgkin's lymphoma.

47 tate, colorectal, and gynecologic cancer and non-Hodgkin's lymphoma.

48 s and cancers such as multiple sclerosis and non-Hodgkin's lymphomas.

49 ont-line treatment in patients with indolent non-Hodgkin's lymphomas.

50 atients with relapsed or refractory indolent non-Hodgkin's lymphomas.

51 e cell lymphoma (MCL) as compared with other non-Hodgkin's lymphomas.

52 inicopathologic entity accounting for 30% of non-Hodgkin's lymphomas.

53 nic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas.

54 emias, and EBV was present in 11/42 (26%) of non-Hodgkin's lymphomas.

55 ere studied on xenografts of RL and HT human non-Hodgkin's lymphomas.

56 in patients with previously treated indolent non-Hodgkin's lymphomas.

57 cs that distinguish them from other types of non-Hodgkin's lymphomas.

58 (CLL) and a number of histologies of B-cell non-Hodgkin's lymphomas.

59 favorable prognosis compared with the B-cell non-Hodgkin's lymphomas.

60 oma 1.34 (1.16, 1.54) and 1.59 (0.88, 2.89); non-Hodgkin's lymphoma 1.15 (0.97, 1.37) and 0.73 (0.28,

61 tive for methylation of the three genes; (4) non-Hodgkin's lymphomas (100%), and leukemias (94%) had

62 In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typical

63 ), breast (19%), lung (6%), pancreatic (6%), non-Hodgkin's lymphoma (6%), melanoma (6%), prostate (4%

64 from our HCV(+) patients (p = 0.004) or from non-Hodgkin's lymphomas (66%, p = 0.003).

65 educed risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased r

66 ificantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell

67 AIDS-related B-cell non-Hodgkin's lymphoma (AIDS-NHL) is a significant cause

68 detected in specific human tumors including non-Hodgkin's lymphomas, although a causative role for t

69 antibodies has proven effective for treating non-Hodgkin's lymphoma and autoimmune disease.

70 20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease.

71 es (mAb) are widely used in the treatment of non-Hodgkin's lymphoma and autoimmune diseases.

72 of reduced intensity regimens in follicular non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

73 ed incidence of transformation to high-grade non-Hodgkin's lymphoma and development of therapy-relate

74 individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues t

75 n gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and includ

76 lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer.

77 groups including increases, of skin cancers, non-Hodgkin's lymphoma and Kaposi's sarcoma and to a les

78 d kidney; the same was true for death due to non-Hodgkin's lymphoma and multiple myeloma.

79 e-colony stimulating factor in patients with non-Hodgkin's lymphoma and multiple myeloma.

80 Hodgkin's lymphoma, and the co-occurrence of non-Hodgkin's lymphoma and other hematologic malignancie

81 d radioimmunotherapy for orbital and adnexal non-Hodgkin's lymphoma and other lymphoproliferative dis

82 ntal data gives insight into the dynamics of Non-Hodgkin's lymphoma and provides a platform to genera

83 rt studies have established the link between non-Hodgkin's lymphoma and SLE.

84 as advanced into phase I clinical studies in non-Hodgkin's lymphoma and solid cancers.

85 ort to assess biochemical changes induced by non-Hodgkin's lymphoma and subcutaneous melanoma.

86 Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advance

87 Bcl-6 is highly expressed in B-cell non-Hodgkin's lymphoma and, in a subset of cases of diff

88 come widely appreciated in aggressive B-cell non-Hodgkin's lymphoma and, more recently, in Hodgkin's

89 gh expression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias.

90 cancer suppression that is often deleted in non-Hodgkin's lymphomas and various epithelial tumors.

91 2.1-3.2) for PTLD, 1.8 (95% CI, 1.4-2.4) for non-Hodgkin's lymphoma, and 0.2 (95% CI, 0.07-4.2) for H

92 sks for prostate, breast, and colon cancers, non-Hodgkin's lymphoma, and multiple myeloma, ranging fr

93 the treatment of acute lymphocytic leukemia, non-Hodgkin's lymphoma, and osteosarcoma.

94 Familial aggregation of non-Hodgkin's lymphoma, and the co-occurrence of non-Hod

95 role of ultraviolet radiation on the risk of non-Hodgkin's lymphoma are warranted.

96 The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype.

97 Most human B-cell non-Hodgkin's lymphomas arise from germinal centers.

98 py has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases ch

99 furan congeners was associated with risk of non-Hodgkin's lymphoma, as were total furans, with 3.5-f

100 eutic agent used in treatment of gliomas and non-Hodgkin's lymphomas, as a multitype age-dependent br

101 Risks of non-Hodgkin's lymphoma associated with each analyte were

102 ultiple pregnancies and an increased risk of non-Hodgkin's lymphoma associated with later age at mena

103 These findings support a reduced risk of non-Hodgkin's lymphoma associated with multiple pregnanc

104 ymphomas (PTCL) are a heterogeneous group of non-Hodgkin's lymphomas associated with an unfavorable p

105 Using a human model of B-cell non-Hodgkin's lymphoma (B-cell NHL), we show that intrat

106 r antibody and is used in the treatment of B-non-Hodgkin's lymphoma (B-NHL).

107 ion with chemotherapy, in the treatment of B-non-Hodgkin's lymphoma (B-NHL).

108 mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine th

109 Most human B cell non-Hodgkin's lymphomas (B-NHLs) derive from germinal ce

110 sion has been suggested as a risk factor for non-Hodgkin's lymphoma, but the results from epidemiolog

111 ing for approximately 40% of newly diagnosed non-Hodgkin's lymphoma cases globally.

112 effect of bryostatin-1 on CD20 expression in non-Hodgkin's lymphoma cells was mediated through the MA

113 nt bryostatin-1 on the expression of CD20 in non-Hodgkin's lymphoma cells.

114 Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma characterized by the t(11;14) chr

115 ymphomas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-

116 phomas (CTCLs) form a heterogeneous group of non-Hodgkin's lymphomas characterized by only poor progn

117 mission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate r

118 B-cell non-Hodgkin's lymphoma comprises biologically and clinic

119 s independently associated with C. glabrata, non-Hodgkin's lymphoma, cytomegalovirus (CMV) antigenemi

120 phoma (BL) is a highly malignant, aggressive non-Hodgkin's lymphoma derived from germinal center B ce

121 Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas derived from T cells that home t

122 aging and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma (especially more aggressive types

123 lso offer clinical benefit for patients with non-Hodgkin's lymphoma, especially for those with aggres

124 Results indicated an increased risk of non-Hodgkin's lymphoma for persons with a positive famil

125 rug Administration approval of rituximab for non-Hodgkin's lymphoma has improved standard chemotherap

126 The extreme pathological diversity of non-Hodgkin's lymphomas has made their accurate histolog

127 The incidence and mortality rates of non-Hodgkin's lymphoma have been increasing worldwide.

128 fidence interval [CI], 1.92-5.11; P<0.0001), non-Hodgkin's lymphoma (HR, 2.37; CI, 1.53-3.68; P=0.000

129 5% confidence interval (95% CI), 4.7 to 18), non-Hodgkin's lymphoma (HR, 3.2; 95% CI, 2.8 to 3.7), Ho

130 neoplasms (HR, 2.26; 95% CI, 1.24 to 4.12), non-Hodgkin's lymphomas (HR, 1.81; 95% CI, 1.12 to 2.93)

131 d PCBs and other organochlorines and risk of non-Hodgkin's lymphoma in a population-based case-contro

132 rom a population-based case-control study of non-Hodgkin's lymphoma in Connecticut women between 1996

133 However, malathion has been associated with non-Hodgkin's lymphoma in several epidemiologic studies.

134 Although the association of non-Hodgkin's lymphoma in SLE is well established, risk

135 DLBCL is the most common non-Hodgkin's lymphoma in the adult population, accounti

136 he similarities between monomorphic PTLD and non-Hodgkin's lymphoma in the general population, our po

137 ected as possible contributors to increasing non-Hodgkin's lymphoma incidence during the latter half

138 A total of 601 histologically confirmed, non-Hodgkin's lymphoma incident cases identified between

139 Subtypes of indolent non-Hodgkin's lymphoma included follicular lymphoma (72

140 eners were associated with increased risk of non-Hodgkin's lymphoma, including coplanar PCBs 156, 180

141 howed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.

142 Non-Hodgkin's lymphoma is a disseminated, highly maligna

143 Non-Hodgkin's lymphoma is considered an AIDS-defining en

144 tral nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, oc

145 miRNAs in clinical samples of EBV-associated non-Hodgkin's lymphomas is unknown.

146 Although NHL (non-Hodgkin's lymphoma) is the fifth leading cause of ca

147 y, which improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly p

148 ollicular lymphoma (FL), an incurable B cell non-Hodgkin's lymphoma, is thought to play a major role

149 Constituting approximately 5 to 8% of all non-Hodgkin's lymphomas, it carries the poorest prognosi

150 ia, tuberculosis), hematological malignancy (non-Hodgkin's lymphoma, leukemia), and renal failure (P

151 hylation profiles for 10 TSGs in 90 cases of non-Hodgkin's lymphomas/leukemias and 56 control tissues

152 SV40 sequences were present in 33/90 (37%) non-Hodgkin's lymphomas/leukemias, and EBV was present i

153 In 22 patients with low-grade non-Hodgkin's lymphoma (LGNHL), the ORR was 63% with 36%

154 ation of lytic virus replication in a B cell non-Hodgkin's lymphoma line by preventing expression of

155 d EBV entry into the lytic cycle in a B cell non-Hodgkin's lymphoma line by upregulating the cellular

156 idence changed in alternating directions for non-Hodgkin's lymphoma, melanoma, and lung, pancreatic,

157 ly confirmed Hodgkin's lymphoma (n = 58) and non-Hodgkin's lymphoma (n = 1,381) cases through linkage

158 tumors (n = 181), mesothelioma (n = 10), and non-Hodgkin's lymphoma (n = 220) were identified through

159 ng new agent for the treatment of follicular non-Hodgkin's lymphoma (NHL) and also diffuse large B-ce

160 increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leu

161 n PTSD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and identified demographic,

162 iagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and

163 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, ye

164 We show in this study that non-Hodgkin's lymphoma (NHL) B cells express B cell-acti

165 sed or refractory Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) but is associated with ther

166 Rituximab treatment of B non-Hodgkin's lymphoma (NHL) cell lines inhibits the con

167 uxan, IDEC-C2B8) has been shown to sensitize non-Hodgkin's lymphoma (NHL) cell lines to chemotherapeu

168 20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic

169 Although preliminary studies suggest that non-Hodgkin's lymphoma (NHL) complicating rheumatoid art

170 National Comprehensive Cancer Network (NCCN) non-Hodgkin's lymphoma (NHL) database with a documented

171 association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throu

172 The incidence of non-Hodgkin's lymphoma (NHL) has doubled over the past t

173 red with younger children with mature B-cell non-Hodgkin's lymphoma (NHL) have been historically cons

174 associated with t(14;18)-defined subsets of non-Hodgkin's lymphoma (NHL) in men.

175 for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients.

176 poptosis induction in human Burkitt's B-cell non-Hodgkin's lymphoma (NHL) Raji cells as determined us

177 city of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab.

178 OH), we compared CT assessed response using non-Hodgkin's lymphoma (NHL) response definitions with N

179 -grade, follicular, or transformed low-grade non-Hodgkin's lymphoma (NHL) that resulted in the regula

180 (NKTCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are assoc

181 ence of t-MDS and t-AML in 746 patients with non-Hodgkin's lymphoma (NHL) treated with the ibritumoma

182 The incidence of non-Hodgkin's lymphoma (NHL) unrelated to HIV infection

183 sorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years po

184 es lowers the risk for melanomas, leukemias, non-Hodgkin's lymphoma (NHL), and ovarian cancer.

185 enormous progress has been made in treating non-Hodgkin's lymphoma (NHL), and some patients can be c

186 hCD59 is highly expressed in B-cell non-Hodgkin's lymphoma (NHL), and upregulation of hCD59

187 hylation of TIMP-2 in 33/90 (36.7%) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripher

188 n shown to be associated with development of non-Hodgkin's lymphoma (NHL), few studies have investiga

189 homa (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased in incidence

190 beled antibody products for the treatment of non-Hodgkin's lymphoma (NHL), radioimmunotherapy (RIT) h

191 The bcl-2 gene is overexpressed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic

192 ermethylation of RASSF1A was detected in 5/6 non-Hodgkin's lymphoma (NHL)-derived cell lines, only ra

193 ago suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).

194 oimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL).

195 the standard of care for many patients with non-Hodgkin's lymphoma (NHL).

196 riety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).

197 leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL).

198 onary involvement is common in patients with non-Hodgkin's lymphoma (NHL).

199 motherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL).

200 b monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).

201 (131)I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL).

202 monly used in the treatment of CD20-positive non-Hodgkin's lymphoma (NHL).

203 tes, disordered immune responses may lead to non-Hodgkin's lymphoma (NHL).

204 in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL).

205 c regimen for patients with CD20+ follicular non-Hodgkin's lymphoma (NHL).

206 rmly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL).

207 apsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).

208 d in the clinical treatment of patients with non-Hodgkin's lymphoma (NHL).

209 determinants remains largely unexplored for non-Hodgkin's lymphoma (NHL).

210 imab, now used in nearly all types of B-cell non-Hodgkin's lymphoma (NHL).

211 rtant therapeutic target in the treatment of non-Hodgkin's lymphoma (NHL).

212 s currently being used in the treatment of B non-Hodgkin's lymphoma (NHL).

213 en diet and nutrient intakes and the risk of non-Hodgkin's lymphoma (NHL).

214 missions (PR) among patients with follicular non-Hodgkin's lymphoma (NHL).

215 fully to treat relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

216 cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL).

217 relapsed or refractory, CD20-positive B-cell non-Hodgkin's lymphoma (NHL).

218 n therapy in 40 patients with CD20+, B-cell, non-Hodgkin's lymphoma (NHL).

219 0 in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

220 ntibody) in patients with recurrent indolent non-Hodgkin's lymphoma (NHL).

221 k of death from many malignancies, including non-Hodgkin's lymphoma (NHL).

222 urvivors of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).

223 tudies to higher cancer incidence, including non-Hodgkin's lymphoma (NHL).

224 s with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL).

225 ation, which may influence susceptibility to non-Hodgkin's lymphoma (NHL).

226 01) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).

227 ation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).

228 ral (HCV) infection has been associated with non-Hodgkin's lymphoma (NHL); however, the results are i

229 persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increase

230 t common malignancies were NMSC (n = 11) and non-Hodgkin's lymphoma (NHL; n = 4) and malignancy risk

231 nts developed a lymphoid disease: 823 (1.2%) non-Hodgkin's lymphomas (NHL), 160 (0.24%) myelomas, 60

232 anism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL).

233 o distinct types of aggressive B- and T-cell non-Hodgkin's lymphomas (NHLs).

234 Non-Hodgkin's lymphoma occurred at a rate 7.6 times that

235 ound to have a significantly reduced risk of non-Hodgkin's lymphoma (odds ratio (OR) = 0.6, 95% confi

236 pite remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologic subtypes, nervo

237 ll lymphoma (CTCL), a heterogeneous group of non-Hodgkin's lymphomas of skin-homing T cells.

238 Radioimmunotherapy for non-Hodgkin's lymphoma often results in surprisingly hig

239 Cancers included: Hodgkin's lymphoma (13), non-Hodgkin's lymphoma (one), pinealoblastoma (one), ton

240 characteristics, including age, diagnosis of non-Hodgkin's lymphoma or Hodgkin's disease, bone marrow

241 ognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.

242 ) for treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma.

243 (OR = 1.5, 95% CI: 1.0, 2.2) and of diffuse non-Hodgkin's lymphoma (OR = 1.7, 95% CI: 1.1, 2.7) for

244 kers, alcohol consumers had a lower risk for non-Hodgkin's lymphoma overall (for >28 drinks/week: adj

245 as not associated with the increased risk of non-Hodgkin's lymphoma overall (odds ratio = 1.0, 95% co

246 e authors also observed an increased risk of non-Hodgkin's lymphoma overall (OR = 1.5, 95% CI: 1.0, 2

247 hand, the authors found no increased risk of non-Hodgkin's lymphoma overall and by subtype of exposur

248 Hodgkin's and many diverse non-Hodgkin's lymphomas overexpress the Hodgkin's diseas

249 RH was likewise found in xenografts of human non-Hodgkin's lymphomas, pancreatic cancer, glioblastoma

250 is tailor-made treatment to large numbers of non-Hodgkin's lymphoma patients.

251 to the high nodal response rates observed in non-Hodgkin's lymphoma patients.

252 stem-cell transplantation, 41 patients with non-Hodgkin's lymphoma received standard-dose 90Y ibritu

253 continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, ev

254 Patients with non-Hodgkin's lymphoma requiring an autologous hematopoi

255 is of acute promyelocytic leukemia (APL) and non-Hodgkin's lymphoma, respectively.

256 The authors analyzed the association between non-Hodgkin's lymphoma risk and family history of hemato

257 lifetime hair-coloring product use increases non-Hodgkin's lymphoma risk.

258 t exposure to organochlorines contributes to non-Hodgkin's lymphoma risk; these risks were most appar

259 former smokers had lower risk of follicular non-Hodgkin's lymphoma (RR = 0.67, 95% CI: 0.52, 0.86).

260 eclinical studies in a murine model of human non-Hodgkin's lymphoma showed cancer cells eradication a

261 cell lymphoma (ALCL), which is a T/null cell non-Hodgkin's lymphoma showing anaplastic morphology wit

262 in combination regimens for the treatment of non-Hodgkin's lymphoma, solid tumors, and earlier presen

263 The risk appears to vary by non-Hodgkin's lymphoma subtypes.

264 omas, it carries the poorest prognosis among non-Hodgkin's lymphoma subtypes.

265 on of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymp

266 phoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that generally affects older indi

267 t's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct featur

268 system lymphoma is a rare form of extranodal non-Hodgkin's lymphoma that is confined to the central n

269 us T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin's lymphoma that may variably involve the ski

270 CL) represent a spectrum of several distinct non-Hodgkin's lymphomas that are characterized by an inv

271 s are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particu

272 ere observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were small fo

273 8F-FDG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy.

274 d 48+ months occurred in three patients with non-Hodgkin's lymphoma, two patients with hormone- and d

275 s currently unknown why an increased risk of non-Hodgkin's lymphoma was found only among women who st

276 sfusion was considered, an increased risk of non-Hodgkin's lymphoma was found only for allogeneic blo

277 The risk of non-Hodgkin's lymphoma was not associated with malathion

278 An almost threefold increased risk of non-Hodgkin's lymphoma was observed among women who repo

279 An increased risk of non-Hodgkin's lymphoma was observed among women who repo

280 . during the summer, a 70% increased risk of non-Hodgkin's lymphoma was observed for the highest tert

281 g biopsy specimens from patients with B-cell non-Hodgkin's lymphoma, we observed a significantly low

282 ers of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among c

283 received previous chemotherapy for indolent non-Hodgkin's lymphoma were treated with a standard 4-we

284 best outcomes were observed in patients with non-Hodgkin's lymphoma, whereas patients with multiple m

285 effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infecti

286 ble safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior

287 clinical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation

288 s stem-cell transplantation in patients with non-Hodgkin's lymphoma who were considered ineligible fo

289 PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapse

290 l, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to ri

291 26% in the bone marrow, and one patient with non-Hodgkin's lymphoma with a p53 splice site mutation s

292 -cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with a poor prognosis.

293 CD79b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs.

294 ad a suntan experienced an increased risk of non-Hodgkin's lymphoma with increasing duration (p(trend

295 mphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care

296 dies have shown a significant association of non-Hodgkin's lymphoma with SLE.

297 vealed a malignant T-cell rich, large B-cell non-Hodgkin's lymphoma with widespread hepatocellular ne

298 breast, cervical, and prostate cancers, and non-Hodgkin's lymphomas), with stratification by sex and

299 eir dioxin-like potency, was associated with non-Hodgkin's lymphoma, with 35% increased risk per 10 T

300 c mechanism shared by common forms of B-cell non-Hodgkin's lymphoma, with direct implications for the